Answers are grounded in this paper and cite their sources.
Ticagrelor, an antiplatelet medication, faces significant challenges in its oral delivery due to poor absorption in the digestive tract, leading to high dosage requirements, variable effectiveness, and delayed onset of action. This research explores the utilization of chitosan nanoparticles to enhance Ticagrelor’s bioavailability and therapeutic efficacy. Employing the Box-Behnken Design (BBD) approach, we optimized the formulation of Ticagrelor-loaded nanoparticles (NPs) and evaluated their physicochemical properties, including particle size, polydispersity index (PDI), and encapsulation efficiency (EE). Our findings indicate that the optimized NPs, with particle sizes ranging from 223.6 nm to 493.8 nm, PDI values between 0.213 and 0.421, and EE values spanning from 83.28% to 92.84%, exhibit significantly improved solubility and stability. Additionally, ex vivo antiplatelet testing demonstrated that Ticagrelor nanoparticles (TG-NPs) achieve a nearly two-fold greater inhibition of platelet aggregation compared to free Ticagrelor (TG) at 4 h and maintain a significant effect up to 24 h. This study provides a robust framework for nanoparticle formulation optimization and underscores the potential of chitosan-based NPs to enhance the oral delivery and therapeutic outcomes of Ticagrelor. Further in vivo evaluations and clinical studies are recommended to confirm these promising results and explore the clinical applications of this nanoparticle-based delivery system.
No takes yet. Share an insight, caveat, or question.
Chavan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: